Skip to main content

Table 2 Outcome of 64 patients treated for recurrent high-grade gliomas using a second series of radiotherapy with or without concurrent chemotherapy

From: Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort

Characteristic

OS-6 (%)

mOS (months)

p=

< 50 years at Re-RT

73 ± 9

9.4 ± 1.4

0.015

≥ 50 years at Re-RT

50 ± 8

5.8 ± 1.4

 

Male

60 ± 9

7.7 ± 0.8

0.669

Female

59 ± 9

7.7 ± 1.7

 

WHO IV

55 ± 7

7.4 ± 1.4

0.009

WHO III

82 ± 12

11.2 ± 10.5

 

Karnofsky performance score < 70

34 ± 14

5.0 ± 1.0

0.002

Karnofsky performance score ≥ 70

66 ± 7

8.1 ± 0.8

 

Time from RT to Re-RT ≤ 12 months

52 ± 11

6.9 ± 2.5

0.140

Time from RT to Re-RT > 12 months

63 ± 8

8.1 ± 1.1

 

No concurrent chemotherapy1

52 ± 10

6.6 ± 2.9

0.001 (3 vs 2)

Carboplatin/etoposide2

54 ± 10

6.7 ± 1.3

0.006 (3 vs 1)

Temozolomide3

92 ± 8

27.0 ± 17.6

0.455 (2 vs 1)

Complete resection before Re-RT

100

17.5 ± 3.4

0.034

Incomplete/no resection before Re-RT

55 ± 7

7.4 ± 1.3

 
  1. OS-6 overall survival rate at six months, mOS median overall survival (months).